{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:02:58Z","timestamp":1715817778226},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2013,7,25]],"date-time":"2013-07-25T00:00:00Z","timestamp":1374710400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s40265-013-0092-5","type":"journal-article","created":{"date-parts":[[2013,7,24]],"date-time":"2013-07-24T18:53:05Z","timestamp":1374691985000},"page":"1395-1403","source":"Crossref","is-referenced-by-count":5,"title":["The Optimal Management of Follicular Lymphoma: An Evolving Field"],"prefix":"10.1007","volume":"73","author":[{"given":"Chaitra","family":"Ujjani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce D.","family":"Cheson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,7,25]]},"reference":[{"issue":"9","key":"92_CR1","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1182\/blood.V93.9.3081","volume":"93","author":"A L\u00f3pez-Guillermo","year":"1999","unstructured":"L\u00f3pez-Guillermo A, Cabanillas F, McDonnell TI, et al. Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma. Blood. 1999;93(9):3081\u20137.","journal-title":"Blood"},{"issue":"5","key":"92_CR2","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-C\u00e9ligny","year":"2004","unstructured":"Solal-C\u00e9ligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258\u201365.","journal-title":"Blood"},{"issue":"27","key":"92_CR3","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","volume":"27","author":"M Federico","year":"2009","unstructured":"Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27(27):4555\u201362.","journal-title":"J Clin Oncol"},{"issue":"7","key":"92_CR4","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1200\/JCO.1998.16.7.2332","volume":"16","author":"P Solal-C\u00e9ligny","year":"1998","unstructured":"Solal-C\u00e9ligny P, Lepage E, Brousse N, et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d\u2019Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol. 1998;16(7):2332\u20138.","journal-title":"J Clin Oncol"},{"issue":"8","key":"92_CR5","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1200\/JCO.2004.10.086","volume":"22","author":"R Advani","year":"2004","unstructured":"Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin\u2019s lymphoma: long-term follow-up of no initial therapy. J Clin Oncol. 2004;22(8):1454\u20139.","journal-title":"J Clin Oncol"},{"issue":"23","key":"92_CR6","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","volume":"311","author":"SJ Horning","year":"1984","unstructured":"Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin\u2019s lymphomas. N Engl J Med. 1984;311(23):1471\u20135.","journal-title":"N Engl J Med"},{"issue":"2 Suppl 2","key":"92_CR7","first-page":"11","volume":"25","author":"RC Young","year":"1988","unstructured":"Young RC, Longo DL, Glatstein E, et al. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol. 1988;25(2 Suppl 2):11\u20136.","journal-title":"Semin Hematol"},{"key":"92_CR8","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","volume":"15","author":"P Brice","year":"1997","unstructured":"Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. J Clin Oncol. 1997;15:1110\u20137.","journal-title":"J Clin Oncol"},{"issue":"9383","key":"92_CR9","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","volume":"362","author":"KM Ardeshna","year":"2003","unstructured":"Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362(9383):516\u201322.","journal-title":"Lancet"},{"issue":"31","key":"92_CR10","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1200\/JCO.2010.33.4474","volume":"30","author":"P Solal-C\u00e9ligny","year":"2012","unstructured":"Solal-C\u00e9ligny P, Bellei M, Marcheselli L, et al. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol. 2012;30(31):3848\u201353.","journal-title":"J Clin Oncol"},{"issue":"31","key":"92_CR11","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1200\/JCO.2012.43.6584","volume":"30","author":"BD Cheson","year":"2012","unstructured":"Cheson BD. Waiting is the hardest part. J Clin Oncol. 2012;30(31):3781\u20132.","journal-title":"J Clin Oncol"},{"issue":"13","key":"92_CR12","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.2003.09.542","volume":"21","author":"RL Haas","year":"2003","unstructured":"Haas RL, Poortmans P, de Jong D, et al. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol. 2003;21(13):2474\u201380.","journal-title":"J Clin Oncol"},{"issue":"27","key":"92_CR13","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1200\/JCO.2011.40.6546","volume":"30","author":"JW Friedberg","year":"2012","unstructured":"Friedberg JW, Byrtek M, Link BK, et al. Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National Lympho Care Study. J Clin Oncol. 2012;30(27):3368\u201375.","journal-title":"J Clin Oncol"},{"issue":"6","key":"92_CR14","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1200\/JCO.1999.17.6.1851","volume":"17","author":"TA Davis","year":"1999","unstructured":"Davis TA, White CA, Grillo-L\u00f3pez AJ, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin\u2019s lymphoma: results of a phase II trial of rituximab. J Clin Oncol. 1999;17(6):1851\u20137.","journal-title":"J Clin Oncol"},{"issue":"9","key":"92_CR15","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s002770000163","volume":"79","author":"M Feuring-Buske","year":"2000","unstructured":"Feuring-Buske M, Kneba M, Unterhalt M, et al. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol. 2000;79(9):493\u2013500.","journal-title":"Ann Hematol"},{"issue":"9","key":"92_CR16","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1093\/annonc\/mds177","volume":"23","author":"P Colombat","year":"2012","unstructured":"Colombat P, Brousse N, Salles G, et al. Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up. Ann Oncol. 2012;23(9):2380\u20135.","journal-title":"Ann Oncol"},{"issue":"12","key":"92_CR17","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","volume":"31","author":"M Federico","year":"2013","unstructured":"Federico M, Luminari S, Dondi A, et al. R-CVP Versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol. 2013;31(12):1506\u201313.","journal-title":"J Clin Oncol"},{"key":"92_CR18","doi-asserted-by":"crossref","unstructured":"Nastoupil L, Sinha R, Byrtek M et al. A comparison of the effectiveness of first-line chemoimmunotherapy regimens for follicular lymphoma used in the United States. Blood (ASH Annual Meeting Abstracts). 2011;118 (Abstract 97).","DOI":"10.1182\/blood.V118.21.97.97"},{"issue":"9","key":"92_CR19","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/00001813-200110000-00003","volume":"12","author":"A Heider","year":"2001","unstructured":"Heider A, Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade NHL. Anticancer Drugs. 2001;12(9):725\u20139.","journal-title":"Anticancer Drugs"},{"issue":"2","key":"92_CR20","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","volume":"26","author":"JW Friedberg","year":"2008","unstructured":"Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory and alkylator-refractory, indolent, and transformed NHL. J Clin Oncol. 2008;26(2):204\u201310.","journal-title":"J Clin Oncol"},{"issue":"1","key":"92_CR21","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cncr.24714","volume":"116","author":"B Kahl","year":"2010","unstructured":"Kahl B, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell NHL. Cancer. 2010;116(1):106\u201314.","journal-title":"Cancer"},{"issue":"15","key":"92_CR22","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","volume":"23","author":"MJ Rummel","year":"2005","unstructured":"Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2005;23(15):3383\u20139.","journal-title":"J Clin Oncol"},{"issue":"27","key":"92_CR23","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","volume":"26","author":"KS Robinson","year":"2008","unstructured":"Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2008;26(27):4473\u20139.","journal-title":"J Clin Oncol"},{"key":"92_CR24","unstructured":"Rummel M, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet (early online publication) 2013. doi: 10.1016\/S0140-6736(12)61763-2Cite ."},{"key":"92_CR25","doi-asserted-by":"crossref","unstructured":"Flinn I, Van der Jagt R, Kahl B, et al. An open-label, randomized study of bendamustine and rituximab compared with rituximab, cyclophosphamide, vincristine, and prednisone or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line treatment of patients with advanced indolent non-Hodgkin\u2019s lymphoma or mantle cell lymphoma: the Bright study. Blood (ASH annual meeting abstracts). 2012;120 (Abstract 902).","DOI":"10.1182\/blood.V120.21.902.902"},{"issue":"25","key":"92_CR26","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1200\/JCO.2010.32.1844","volume":"29","author":"N Fowler","year":"2011","unstructured":"Fowler N, Kahl BS, Lee P, et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. J Clin Oncol. 2011;29(25):3389\u201395.","journal-title":"J Clin Oncol"},{"issue":"10","key":"92_CR27","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2010-11-314708","volume":"117","author":"J Friedberg","year":"2011","unstructured":"Friedberg J, Vose J, Kelly J, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed\/refractory indolent and mantle cell NHL. Blood. 2011;117(10):2807\u201312.","journal-title":"Blood"},{"issue":"29","key":"92_CR28","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","volume":"28","author":"G Martinelli","year":"2010","unstructured":"Martinelli G, Schmitz SF, Utiger U, et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98. J Clin Oncol. 2010;28(29):4480\u20134.","journal-title":"J Clin Oncol"},{"key":"92_CR29","doi-asserted-by":"crossref","unstructured":"Ardeshna KM, Smith P, Qian W, et al. An Intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a): a preliminary analysis. Blood (ASH annual meeting abstracts). 2010;116 (Abstract 6).","DOI":"10.1182\/blood.V116.21.6.6"},{"key":"92_CR30","doi-asserted-by":"crossref","unstructured":"Kahl B, Hong F, Williams M, et al. Results of Eastern Cooperative Oncology Group protocol E4402 (RESORT): a randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma. Blood (ASH annual meeting abstracts). 2011;118 (Abstract 6).","DOI":"10.1182\/blood.V118.21.LBA-6.bld0076_P3_LBA-6"},{"issue":"9759","key":"92_CR31","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2\u00a0years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377(9759):42\u201351.","journal-title":"Lancet"},{"issue":"15","key":"92_CR32","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","volume":"20","author":"T Witzig","year":"2002","unstructured":"Witzig T, Linn I, Gordon L, et al. Treatment with ibritumomab tiuxetan radiotherapy in patients with rituximab-refractory follicular non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2002;20(15):3262\u20139.","journal-title":"J Clin Oncol"},{"issue":"19","key":"92_CR33","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","volume":"19","author":"M Kaminski","year":"2001","unstructured":"Kaminski M, Zelenetz A, Press O, et al. Pivotal study of iodine-131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2001;19(19):3918\u201328.","journal-title":"J Clin Oncol"},{"issue":"32","key":"92_CR34","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","volume":"26","author":"F Morschhauser","year":"2008","unstructured":"Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with Yttrium-90\u2013ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008;26(32):5156\u201364.","journal-title":"J Clin Oncol"},{"issue":"3","key":"92_CR35","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1200\/JCO.2012.42.4101","volume":"31","author":"OW Press","year":"2013","unstructured":"Press OW, Unger JM, Rimsza LM, et al. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus 131iodine\u2013tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol. 2013;31(3):314\u201320.","journal-title":"J Clin Oncol"},{"key":"92_CR36","unstructured":"Zevalin Package Insert. (2011). http:\/\/www.zevalin.com\/wp-content\/uploads\/2012\/03\/Zevalin_Package_Insert.pdf ."},{"issue":"12","key":"92_CR37","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2004-12-4690","volume":"105","author":"JM Bennett","year":"2005","unstructured":"Bennett JM, Kaminski MS, Leonard JP, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood. 2005;105(12):4576\u201382.","journal-title":"Blood"},{"issue":"18","key":"92_CR38","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1200\/JCO.2009.27.8325","volume":"28","author":"BK Link","year":"2010","unstructured":"Link BK, Martin P, Kaminski MS, et al. Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study. J Clin Oncol. 2010;28(18):3035\u201341.","journal-title":"J Clin Oncol"},{"key":"92_CR39","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825\u201333.","journal-title":"J Clin Oncol"},{"issue":"17","key":"92_CR40","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","volume":"28","author":"MH Oers van","year":"2010","unstructured":"van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin\u2019s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28(17):2853\u20138.","journal-title":"J Clin Oncol"},{"issue":"8","key":"92_CR41","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","volume":"111","author":"M Ladetto","year":"2008","unstructured":"Ladetto M, De Marco F, Benedetti F, et al. Prospective, multicenter randomized GITMO\/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood. 2008;111(8):4004\u201313.","journal-title":"Blood"},{"issue":"16","key":"92_CR42","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1182\/blood-2011-09-378323","volume":"119","author":"M Czuczman","year":"2012","unstructured":"Czuczman M, Fayad L, Delwail V, et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood. 2012;119(16):3698\u2013704.","journal-title":"Blood"},{"key":"92_CR43","doi-asserted-by":"crossref","unstructured":"Fowler N, Kahanic S, Forero A, et al. Results of a phase II study with bendamustine and ofatumumab in untreated indolent B-cell non-Hodgkin\u2019s lymphoma. Blood. (ASH annual meeting abstracts). 2011;118 (Abstract 778).","DOI":"10.1182\/blood.V118.21.778.778"},{"key":"92_CR44","doi-asserted-by":"crossref","unstructured":"Czuczman M, Viardot A, Hess G, et al. Ofatumumab combined with CHOP in previously untreated patients with follicular lymphoma (FL). J Clin Oncol. (ASCO annual meeting abstracts). 2010;28(15) (Abstract 8042).","DOI":"10.1200\/jco.2010.28.15_suppl.8042"},{"key":"92_CR45","doi-asserted-by":"crossref","unstructured":"Sehn L, Goy A, Offner F, et al. Randomized phase II trial comparing GA101 (obinutuzumab) with rituximab in patients with relapsed CD20 indolent B-cell non-Hodgkin lymphoma: preliminary analysis of the GAUSS study. Blood. (ASH annual meeting abstracts). 2011;118 (Abstract 269).","DOI":"10.1182\/blood.V118.21.269.269"},{"issue":"16","key":"92_CR46","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.2003.01.082","volume":"21","author":"J Leonard","year":"2003","unstructured":"Leonard J, Coleman M, Ketas J, et al. Phase I\/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2003;21(16):3051\u20139.","journal-title":"J Clin Oncol"},{"key":"92_CR47","doi-asserted-by":"crossref","unstructured":"Grant B, Leonard J, Johnson J, et al. Combination biologic therapy as initial treatment for follicular lymphoma: initial results from CALGB 50701\u2014a phase II trial of extended induction epratuzumab (anti-CD22) and rituximab (anti-CD20). Blood (ASH annual meeting abstracts). 2010;116 (Abstract 427).","DOI":"10.1182\/blood.V116.21.427.427"},{"key":"92_CR48","doi-asserted-by":"crossref","unstructured":"Forero A, Hamadani M, Fanale M, et al. MEDI-551, a humanized monoclonal anti-CD19, in adults with relapsed or refractory advanced B-cell malignancies: results from a phase 1\/2 study. Blood (ASH annual meeting abstracts). 2012;120 (Abstract 3677).","DOI":"10.1182\/blood.V120.21.3677.3677"},{"key":"92_CR49","doi-asserted-by":"crossref","unstructured":"Goy A, Leach J, Ehmann W, et al. Inotuzumab ozogamicin (CMC-544) in patients with indolent B-cell NHL that is refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy: preliminary safety and efficacy from a phase 2 trial. Blood (ASH annual meeting abstracts). 2010;116 (Abstract 430).","DOI":"10.1182\/blood.V116.21.430.430"},{"key":"92_CR50","doi-asserted-by":"crossref","unstructured":"Palanca-Wessels M, Flinn I, Sehn L, et al. A phase I study of the anti-CD79b antibody-drug conjugate (ADC) DCDS4501A targeting CD79b in relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma (NHL). Blood (ASH annual meeting abstracts). 2012;120 (Abstract 56).","DOI":"10.1182\/blood.V120.21.56.56"},{"key":"92_CR51","doi-asserted-by":"crossref","unstructured":"Advani R, Lebovic D, Brunvand M, et al. A phase I study of DCDT2980S, an antibody-drug conjugate (ADC) targeting CD22, in relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma (NHL). Blood (ASH annual meeting abstracts). 2012;120 (Abstract 59).","DOI":"10.1182\/blood.V120.21.59.59"},{"key":"92_CR52","doi-asserted-by":"crossref","unstructured":"Leonard J, Jung S, Johnson J, et al. CALGB 50401: a randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma. J Clin Oncol. (ASCO meeting abstracts). 2012;30(15) (Abstract 8000).","DOI":"10.1200\/jco.2012.30.15_suppl.8000"},{"key":"92_CR53","doi-asserted-by":"crossref","unstructured":"Fowler N, Neelapu S, Hagemeister F, et al. Lenalidomide and rituximab for untreated indolent lymphoma: final results of a phase II study. Blood (ASH annual meeting abstracts). 2012;120 (Abstract 901).","DOI":"10.1182\/blood.V120.21.901.901"},{"key":"92_CR54","doi-asserted-by":"crossref","unstructured":"Fowler N, Advani R, Sharman J, et al. The Bruton\u2019s tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma. Blood (ASH annual meeting abstracts). 2012;120 (Abstract 156).","DOI":"10.1182\/blood.V120.21.156.156"},{"key":"92_CR55","doi-asserted-by":"crossref","unstructured":"Kahl B, Byrd J, Flinn I, et al. Clinical safety and activity in a phase 1 study of CAL-101, and isoform-selective inhibitor of phosphatidylinositol 3-kinase p110\u03b4, in patients with relapsed or refractory non-Hodgkin lymphoma. Blood. (ASH annual meeting abstracts). 2010;116 (Abstract 1777).","DOI":"10.1182\/blood.V116.21.1777.1777"},{"key":"92_CR56","doi-asserted-by":"crossref","unstructured":"Fowler N, de Vos S, Schreeder M, et al. Combinations of the phosphatidylinositol 3-kinase-delta (PI3K{delta}) inhibitor GS-1101 (CAL-101) with rituximab and\/or bendamustine are tolerable and highly active in previously treated, indolent non-Hodgkin lymphoma: results from a phase I study. Blood. (ASH annual meeting abstracts). 2012;120 (Abstract 3645).","DOI":"10.1182\/blood.V120.21.3645.3645"},{"key":"92_CR57","doi-asserted-by":"crossref","unstructured":"Davids M, Roberts A, Anderson M, et al. The BCL-2-specific BH3-mimetic ABT-199 (GDC-0199) is active and well-tolerated in patients with relapsed non-Hodgkin lymphoma: interim results of a phase I study. Blood. (ASH annual meeting abstracts). 2012;120 (Abstract 304).","DOI":"10.1182\/blood.V120.21.304.304"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0092-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-013-0092-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0092-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T08:17:21Z","timestamp":1715761041000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-013-0092-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,25]]},"references-count":57,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["92"],"URL":"https:\/\/doi.org\/10.1007\/s40265-013-0092-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,25]]}}}